Christian Hartinger
#60,117
Most Influential Person Now
New Zealand bioinorganic chemist known for his work in metal-based anticancer drugs
Christian Hartinger's AcademicInfluence.com Rankings
Christian Hartingerchemistry Degrees
Chemistry
#3074
World Rank
#4062
Historical Rank
Inorganic Chemistry
#279
World Rank
#294
Historical Rank
Download Badge
Chemistry
Christian Hartinger's Degrees
- PhD Chemistry University of Vienna
- Masters Chemistry University of Vienna
Why Is Christian Hartinger Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christian G. Hartinger is an Austrian-born New Zealand bioinorganic chemist known for his work in metal-based anticancer drugs. In 2022 he was elected a Fellow of the Royal Society Te Apārangi. Scientific career Hartinger studied chemistry at the University of Vienna, earning his MSc in 1999 and his PhD in 2001 under Bernhard Keppler. He was an Erwin Schrödinger Fellow with Paul Dyson at the École Polytechnique Fédérale de Lausanne from 2006 to 2008 and obtained his habilitation at the University of Vienna in 2009. In 2011, Hartinger was appointed the position of associate professor at Waipapa Taumata Rau, where he currently serves and in 2015 was promoted to professor.
Christian Hartinger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). (2006) (805)
- Bioorganometallic chemistry--from teaching paradigms to medicinal applications. (2009) (760)
- Antitumour metal compounds: more than theme and variations. (2008) (738)
- KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients (2008) (607)
- Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. (2006) (498)
- Challenges and Opportunities in the Development of Organometallic Anticancer Drugs (2012) (458)
- Anticancer activity of metal complexes: involvement of redox processes. (2011) (398)
- The development of RAPTA compounds for the treatment of tumors (2016) (336)
- Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. (2008) (246)
- Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. (2008) (226)
- The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways (2008) (216)
- Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. (2018) (213)
- Opening the lid on piano-stool complexes: An account of ruthenium(II)–arene complexes with medicinal applications (2014) (205)
- Resistance against novel anticancer metal compounds: differences and similarities. (2008) (204)
- Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study (2009) (201)
- Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. (2006) (199)
- Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity. (2007) (184)
- Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy (2004) (181)
- Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds (2008) (161)
- A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. (2011) (152)
- Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. (2009) (148)
- Carbohydrate-metal complexes and their potential as anticancer agents. (2008) (138)
- Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. (2005) (137)
- Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. (2012) (132)
- Platinum metallodrug‐protein binding studies by capillary electrophoresis‐inductively coupled plasma‐mass spectrometry: Characterization of interactions between Pt(II) complexes and human serum albumin (2004) (126)
- Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. (2007) (125)
- Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. (2013) (120)
- Development of anticancer agents: wizardry with osmium. (2014) (120)
- Platinum nanoparticles and their cellular uptake and DNA platination at non-cytotoxic concentrations (2011) (119)
- Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies (2012) (116)
- Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands. (2012) (115)
- Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. (2013) (115)
- Impact of the Halogen Substitution Pattern on the Biological Activity of Organoruthenium 8-Hydroxyquinoline Anticancer Agents (2015) (108)
- Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro. (2009) (107)
- In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. (2008) (103)
- Physicochemical Studies and Anticancer Potency of Ruthenium η6-p-Cymene Complexes Containing Antibacterial Quinolones (2011) (102)
- Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)]. (2008) (101)
- Novel metal(II) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents (2013) (99)
- Anticancer metallodrugs: where is the next cisplatin? (2018) (99)
- Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. (2011) (97)
- Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter? (2010) (94)
- Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins (2005) (93)
- Platinum group metallodrug‐protein binding studies by capillary electrophoresis – inductively coupled plasma‐mass spectrometry: A further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins (2006) (92)
- Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. (2009) (91)
- Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. (2008) (91)
- CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. (2008) (89)
- Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds. (2008) (89)
- Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry (2010) (87)
- Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic Compounds (2009) (85)
- Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis. (2005) (79)
- Capillary electrophoresis hyphenated to inductively coupled plasma‐mass spectrometry: A novel approach for the analysis of anticancer metallodrugs in human serum and plasma (2008) (79)
- Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences. (2010) (78)
- A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. (2004) (78)
- Mass spectrometric analysis of ubiquitin–platinum interactions of leading anticancer drugs: MALDI versus ESI (2007) (78)
- From Pyrone to Thiopyrone Ligands−Rendering Maltol-Derived Ruthenium(II)−Arene Complexes That Are Anticancer Active in Vitro (2009) (76)
- Pyrone derivatives and metals: From natural products to metal-based drugs (2011) (74)
- Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. (2012) (74)
- An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. (2017) (73)
- KP1019, A New Redox-Active Anticancer Agent — Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients (2009) (73)
- Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics. (2011) (73)
- Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. (2005) (73)
- Anticancer Ruthenium(η 6 - p -cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives (2014) (72)
- 3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands. (2013) (72)
- Suzuki Coupling Reactions in Ether-Functionalized Ionic Liquids: The Importance of Weakly Interacting Cations (2008) (71)
- DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media. (2009) (70)
- Bioorganometallic Chemistry — From Teaching Paradigms to Medicinal Applications (2009) (69)
- Synthesis, Cytotoxicity, and COMPARE Analysis of Ferrocene and [3]Ferrocenophane Tetrasubstituted Olefin Derivatives against Human Cancer Cells (2010) (68)
- Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: synthesis, solution speciation and bioactivity. (2014) (68)
- Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta (2009) (64)
- Organometallic Antitumour Agents with Alternative Modes of Action (2010) (62)
- From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands. (2011) (60)
- Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety (2009) (57)
- LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma. (2011) (57)
- Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity. (2015) (56)
- Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex (2012) (56)
- Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds (2012) (54)
- High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides. (2008) (54)
- Analysis of Platinum Adducts with DNA Nucleotides and Nucleosides by Capillary Electrophoresis Coupled to ESI‐MS: Indications of Guanosine 5′‐Monophosphate O6–N7 Chelation (2004) (53)
- Nitrile-functionalized pyrrolidinium ionic liquids as solvents for cross-coupling reactions involving in situ generated nanoparticle catalyst reservoirs. (2010) (53)
- Anticancer metallodrug research analytically painting the “omics” picture—current developments and future trends (2013) (52)
- Half-sandwich ruthenium(II) biotin conjugates as biological vectors to cancer cells. (2015) (52)
- Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands. (2012) (52)
- CE in anticancer metallodrug research – an update (2007) (52)
- Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins. (2012) (52)
- Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity. (2008) (52)
- Reversion of Structure-Activity Relationships of Antitumor Platinum Complexes by Acetoxime but Not Hydroxylamine Ligands (2007) (51)
- Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. (2013) (51)
- Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. (2012) (48)
- Capillary electrophoresis in anti‐cancer metallodrug research: Advances and future challenges (2003) (48)
- Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. (2014) (47)
- Probing the stability of serum protein–ruthenium(III) drug adducts in the presence of extracellular reductants using CE (2007) (46)
- Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient. (2005) (46)
- Ruthenium and Other Non‐Platinum Anticancer Compounds (2011) (46)
- Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs (2012) (46)
- The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE‐MS techniques (2009) (45)
- {(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo. (2010) (44)
- Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-κ2N, O)platinum(II): a representative of novel pH sensitive anticancer platinum complexes (2004) (43)
- Metallodrug research and analysis using capillary electrophoresis (2006) (43)
- Chemical imaging and assessment of cadmium distribution in the human body. (2019) (42)
- Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology (2006) (42)
- The first example of MEEKC‐ICP‐MS coupling and its application for the analysis of anticancer platinum complexes (2010) (42)
- Metal complexes of benzimidazole derived sulfonamide: Synthesis, molecular structures and antimicrobial activity (2016) (42)
- Metabolization of [Ru(η6-C6H5CF3)(pta)Cl2]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand (2010) (41)
- A glucose derivative as natural alternative to the cyclohexane‐1,2‐diamine ligand in the anticancer drug oxaliplatin? (2007) (40)
- From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents. (2018) (39)
- Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems. (2016) (38)
- Fragmentation methods on the balance: unambiguous top–down mass spectrometric characterization of oxaliplatin–ubiquitin binding sites (2012) (38)
- Modifying the structure of dinuclear ruthenium complexes with antitumor activity (2008) (38)
- A low symmetry heterobimetallic [PdPtL4]4+ cage: assembly, guest binding and stimulus-induced switching. (2020) (36)
- Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. (2018) (35)
- A new target for gold(I) compounds: glutathione-S-transferase inhibition by auranofin. (2013) (35)
- New Insights into the Chemistry of the Antineoplastic Lanthanum Complex Tris(1,10-phenanthroline)tris(thiocyanato-κN)lanthanum(III) (KP772) and Its Interaction with Biomolecules (2009) (34)
- Tumor‐inhibiting platinum(II) complexes with aminoalcohol ligands: Comparison of the mode of action by capillary electrophoresis and electrospray ionization‐mass spectrometry (2003) (32)
- Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand. (2016) (32)
- Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl2 Complexes. (2020) (31)
- (Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity toward Biomolecules (2018) (31)
- Elucidation of the Interactions of an Anticancer Ruthenium Complex in Clinical Trials with Biomolecules Utilizing Capillary Electrophoresis Hyphenated to Inductively Coupled Plasma‐Mass Spectrometry. Short Communication (2008) (30)
- Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis. (2007) (30)
- Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. (2013) (28)
- Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)–(η6-Arene) Complexes (2010) (28)
- Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay. (2017) (28)
- Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity (2015) (28)
- Mannich products of kojic acid and N-heterocycles and their Ru(II)-arene complexes: Synthesis, characterization and stability (2010) (27)
- Hydroxyquinoline-derived anticancer organometallics: Introduction of amphiphilic PTA as an ancillary ligand increases their aqueous solubility. (2019) (26)
- RutheniumII(η6-arene) Complexes of Thiourea Derivatives: Synthesis, Characterization and Urease Inhibition (2014) (26)
- An internal fluorescent probe based on anthracene to evaluate cation-anion interactions in imidazolium salts. (2010) (26)
- Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os. (2017) (26)
- Interactions of the carrier ligands of antidiabetic metal complexes with human serum albumin: a combined spectroscopic and separation approach with molecular modeling studies. (2011) (25)
- Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity. (2019) (25)
- Making organoruthenium complexes of 8-hydroxyquinolines more hydrophilic: impact of a novel l-phenylalanine-derived arene ligand on the biological activity. (2018) (24)
- DNA interactions of pH-sensitive, antitumor bis(aminoalcohol)dichloroplatinum(II) complexes. (2006) (24)
- Novel glucose-ferrocenyl derivatives: synthesis and properties (2002) (23)
- Anticancer Ru(η6-p-cymene) complexes of 2-pyridinecarbothioamides: A structure-activity relationship study. (2017) (23)
- Structural Modifications of the Antiinflammatory Oxicam Scaffold and Preparation of Anticancer Organometallic Compounds (2019) (23)
- Cationic Ru(η6‐p‐cymene) Complexes of 3‐Hydroxy‐4‐pyr(id)ones – Lipophilic Triphenylphosphine as Co‐Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents (2017) (23)
- The metalation of hen egg white lysozyme impacts protein stability as shown by ion mobility mass spectrometry, differential scanning calorimetry, and X-ray crystallography. (2017) (23)
- Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents (2021) (23)
- Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands (2021) (22)
- Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC–ICP–MS (2018) (22)
- Solution equilibria of anticancer ruthenium(II)-(η(6)-p-cymene)-hydroxy(thio)pyr(id)one complexes: impact of sulfur vs. oxygen donor systems on the speciation and bioactivity. (2013) (22)
- DNA damaging properties of single walled carbon nanotubes in human colon carcinoma cells (2013) (22)
- Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry (2016) (21)
- Capillary electrophoretic methods in the development of metal‐based therapeutics and diagnostics: New methodology and applications (2012) (21)
- Solution equilibrium studies on anticancer ruthenium(II)-η6- p-cymene complexes of 3-hydroxy-2(1H)-pyridones (2013) (20)
- Biodistribution of anti‐diabetic Zn(II) complexes in human serum and in vitro protein‐binding studies by means of CZE–ICP‐MS (2009) (20)
- A Bioactive l-Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action. (2018) (20)
- Tumour-inhibiting platinum(II) complexes with aminoalcohol ligands: biologically important transformations studied by micellar electrokinetic chromatography, nuclear magnetic resonance spectroscopy and mass spectrometry. (2005) (20)
- Flavonoid‐Based Organometallics with Different Metal Centers – Investigations of the Effects on Reactivity and Cytotoxicity (2016) (20)
- Phosphite‐Derivatized Ruthenium‐Carbohydrate Complexes in the Catalytic Hydration of Nitriles. Short Communication (2008) (20)
- Extravasation of Pt-based chemotherapeutics - bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). (2015) (20)
- Advanced metallomics methods in anticancer metallodrug mode of action studies (2017) (19)
- DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity. (2017) (19)
- The Hydration of Chloroacetonitriles Catalyzed by Mono‐ and Dinuclear RuII‐ and OsII‐Arene Complexes (2008) (19)
- Biological properties of ruthenium(II)/(III) complexes with flavonoids as ligands (2021) (19)
- RuII(η6‐p‐cymene) Complexes of Bioactive 1,2‐Benzothiazines: Protein Binding vs. Antitumor Activity (2016) (19)
- Synthesis of ferrocenylglucose phosphonite and bisphosphinite: Pd(II) and Pt(II) complexes, Pd-catalyzed allylic alkylation (2002) (19)
- Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity (2017) (17)
- Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct Formation. (2021) (17)
- Capillary zone electrophoresis and capillary zone electrophoresis-electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone oxime)platinum(II)] complexes in aqueous solutions. (2012) (17)
- Organometallic Ruthenium and Osmium Compounds of Pyridin‐2‐ and ‐4‐ones as Potential Anticancer Agents (2012) (16)
- Rhodium(Cp*) Compounds with Flavone‐derived Ligand Systems: Synthesis and Characterization (2013) (16)
- Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adduct. (2018) (16)
- Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation. (2018) (16)
- Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes (2013) (16)
- Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes. (2016) (15)
- Trapping unstable benzoquinone analogues by coordination to a [(η(5)-C(5)Me(5))Ir] fragment and the anticancer activity of the resulting complexes. (2010) (15)
- Coordination Chemistry of Organoruthenium Compounds with Benzoylthiourea Ligands and their Biological Properties. (2019) (15)
- Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes (2013) (15)
- A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2′-deoxyguanosine 5′-monophosphate (dGMP) (2013) (14)
- Expanding on the Structural Diversity of Flavone-Derived RutheniumII(ƞ6-arene) Anticancer Agents (2015) (14)
- A Multitargeted Approach in the Discovery of an Organorhodium Anticancer Agent Based On Vorinostat as a Potent Histone Deacetylase Inhibitor. (2020) (14)
- Physicochemical studies on the copper(II) binding by glycated collagen telopeptides. (2015) (13)
- Glucose ferrocenyl-oxazolines : Coordination behavior toward [Pd(η3-allyl)Cl]2 studied by ESI-MS (2005) (13)
- Solution equilibrium studies of anticancer ruthenium(II)-η6-p-cymene complexes of pyridinecarboxylic acids (2014) (12)
- Antitumor Metallodrugs that Target Proteins. (2018) (11)
- 1,1'‐Bis(oxazolin‐2‐yl)ferrocenes: An Investigation of Their Complexation Behavior toward [Pd(η3‐allyl)Cl]2 (2005) (11)
- Functionalization of Ruthenium(II)(η6 -p-cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. (2017) (11)
- Cover Picture: An Internal Fluorescent Probe Based on Anthracene to Evaluate Cation–Anion Interactions in Imidazolium Salts (Chem. Eur. J. 22/2010) (2010) (11)
- Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies (2016) (11)
- Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(η6-cymene)(PPh2(o-C6H4O)-κ2-P,O)(pta)]+ and an investigation of its cytotoxic effects (2010) (10)
- Quinoline-para-quinones and metals: coordination-assisted formation of quinoline-ortho-quinones. (2018) (10)
- Synthesis of [RuII(η6-p-cymene)(PPh3)(L)Cl]PF6 complexes with carbohydrate-derived phosphites, imidazole or indazole co-ligands (2012) (10)
- A Combined Spectroscopic and Protein Crystallography Study Reveals Protein Interactions of RhI(NHC) Complexes at the Molecular Level. (2020) (10)
- Efficiently Detecting Metallodrug–Protein Adducts: Ion Trap versus Time‐of‐Flight Mass Analyzers (2014) (10)
- Synthesis and in vitro Biological Evaluation of Ferrocenyl Side‐Chain‐Functionalized Paclitaxel Derivatives (2017) (10)
- Understanding the interactions of diruthenium anticancer agents with amino acids (2018) (10)
- Hybrid compounds from chalcone and 1,2-benzothiazine pharmacophores as selective inhibitors of alkaline phosphatase isozymes. (2018) (9)
- The rearrangement of tosylated flavones to 1′-(alkylamino)aurones with primary amines (2015) (9)
- Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs. (2020) (9)
- Ein Organoruthenium‐Tumortherapeutikum mit unerwartet hoher Selektivität für Plectin (2017) (9)
- Anthracenyl Functionalization of Half-Sandwich Carbene Complexes: In Vitro Anticancer Activity and Reactions with Biomolecules. (2021) (9)
- Organoruthenium and Organoosmium Complexes of 2-Pyridinecarbothioamides Functionalized with a Sulfonamide Motif: Synthesis, Cytotoxicity and Biomolecule Interactions. (2018) (9)
- A Reduced‐Symmetry Heterobimetallic [PdPtL 4 ] 4+ Cage: Assembly, Guest Binding, and Stimulus‐Induced Switching (2020) (8)
- Mustards-Derived Terpyridine-Platinum Complexes as Anticancer Agents: DNA Alkylation vs Coordination. (2021) (8)
- Heterotrimetallic Double Cavity Cages: Syntheses and Selective Guest Binding (2022) (8)
- A one step/one pot synthesis of N,N-bis(phosphonomethyl)amino acids and their effects on adipogenic and osteogenic differentiation of human mesenchymal stem cells. (2009) (8)
- Gold(III) Compounds as Anticancer Agents: Relevance of Gold—Protein Interactions for Their Mechanism of Action (2008) (8)
- Capillary electrophoresis in metallodrug development. (2015) (8)
- Synthesis, crystal structures, and electrospray ionisation mass spectrometry investigations of ether- and thioether-substituted ferrocenes (2003) (8)
- Opening the Lid on Piano‐Stool Complexes: An Account of Ruthenium(II)—Arene Complexes with Medicinal Applications (2014) (7)
- Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells (2021) (7)
- AAS, XRF, and MS Methods in Chemical Biology of Metal Complexes (2014) (7)
- Methyl-substituted trans-1,2-cyclohexanediamines as new ligands for oxaliplatin-type complexes (2008) (7)
- Bis- and tris-bicyclophosphites of d-glucofuranoside. Unexpected catalysis of P(III/V)-oxidation by triethylamine (2005) (6)
- Heptadentate, Octadentate, Or Even Nonadentate? Denticity in the Unexpected Formation of an All-Carbon Donor-Atom Ligand in RhIII(Cp*)(Anthracenyl-NHC) Complexes. (2021) (6)
- Thiourea-Derived Chelating Ligands and Their Organometallic Compounds: Investigations into Their Anticancer Activity (2020) (6)
- Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands (2020) (6)
- Linked Metal-cluster Systems: Isolation and Characterisation of {anti-[(p-cymene)RuCl]-μ-[κ2-P,P′;κ1-P′′-(PPh2CH2)3CMe]-[AuPt3(CO)3(PCy3)3]}(PF6)2 (2008) (5)
- A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor (2020) (5)
- Gel electrophoresis in combination with laser ablation–inductively coupled plasma mass spectrometry to quantify the interaction of cisplatin with human serum albumin (2019) (5)
- Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. (2014) (5)
- Hyphenation of capillary electrophoresis to inductively coupled plasma mass spectrometry with a modified coaxial sheath-flow interface. (2018) (5)
- High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes (2021) (5)
- Ruthenium Anticancer Agents—From Cisplatin Analogues to Rational Drug Design (2017) (5)
- Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer (2021) (5)
- Triazolyl‐Functionalized N‐Heterocyclic Carbene Half‐Sandwich Compounds: Coordination Mode, Reactivity and in vitro Anticancer Activity (2021) (5)
- Cobalt complexes as internal standards for capillary zone electrophoresis–mass spectrometry studies in biological inorganic chemistry (2017) (5)
- Impact of the Metal Center and Leaving Group on the Anticancer Activity of Organometallic Complexes of Pyridine-2-carbothioamide † (2021) (5)
- Electrospray ionization mass spectrometric study on the coordination behavior of dacarbazine towards transition metal ions (2006) (4)
- Tracing the anticancer compound [RuII(η6-p-cymene)(8-oxyquinolinato)Cl] in a biological environment by mass spectrometric methods. (2021) (4)
- 1,1,3,3-Tetramethyl-1,3-disila-2-oxa[3]ferrocenophane: improved synthesis and new crystal structure (2002) (4)
- Ligand Design in Medicinal Inorganic Chemistry. Edited by Tim Storr. (2015) (4)
- 5-Hydroxy-2-methyl-4H-pyran-4-one (2009) (3)
- Homodinuclear organometallics of ditopic N,N-chelates: Synthesis, reactivity and in vitro anticancer activity (2021) (3)
- Medicinal Chemistry (2019) (3)
- Pyrone Derivatives and Metals: From Natural Products to Metal‐Based Drugs (2011) (3)
- Comparative solution studies and cytotoxicity of gallium(III) and iron(III) complexes of 3-hydroxy-2(1H)-pyridinones (2019) (3)
- The Analysis of Therapeutic Metal Complexes and Their Biomolecular Interactions (2017) (3)
- Dalton Discussion 10: Applications of Metals in Medicine and Healthcare (2008) (3)
- Incorporation of β‐Alanine in Cu(II) ATCUN Peptide Complexes Increases ROS Levels, DNA Cleavage and Antiproliferative Activity (2021) (3)
- Synthetic Strategy Towards Heterodimetallic Half-Sandwich Complexes Based on a Symmetric Ditopic Ligand (2021) (2)
- Isolierung instabiler Benzochinonanaloga durch Koordination an ein [(η5‐C5Me5)Ir]‐Fragment und tumorhemmende Aktivität der resultierenden Komplexe (2010) (2)
- Dan David Prize: C. A. Mirkin and A. P. Alivisatos / SBIC Early Career Award: G. G. Hartinger / Royal Medal: J. M. Thomas. (2016) (2)
- Reprint of: Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies (2017) (2)
- Correction to “(Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity Toward Biomolecules” (2018) (2)
- From the hypothesis-driven development of organometallic anticancer drugs to new methods in mode of action studies (2020) (2)
- On the Coordination Properties of New Bicyclophosphite-Carbohydrates (2005) (2)
- In-flow SAXS investigation of whey protein isolate hydrolyzed by bromelain (2021) (2)
- Impact of the ferrocenyl group on cytotoxicity and KSP inhibitory activity of ferrocenyl monastrol conjugates. (2021) (1)
- Corrigendum: Cavity-Containing [Fe2L3]4+ Helicates: An Examination of Host-Guest Chemistry and Cytotoxicity (2021) (1)
- Metal Compounds as Kinase and Phosphatase Inhibitors in Drug Development: The Role of the Metal and Ligands (2015) (1)
- Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds (2012) (1)
- Substitution of the chlorido ligand for PPh3 in anticancer organoruthenium complexes of sulfonamide functionalized pyridine-2-carbothioamides leads to high cytotoxic activity (2022) (1)
- Cavity-Containing [Fe2L3]4+ Helicates: An Examination of Host-Guest Chemistry and Cytotoxicity (2021) (1)
- Impact of Coordination Mode and Ferrocene Functionalization on the Anticancer Activity of N-Heterocyclic Carbene Half-Sandwich Complexes. (2022) (1)
- Correction: Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adduct. (2019) (1)
- New C2-Chiral 1,1′-Bis(Oxazoline-2-YL)-Ferrocenes – Synthesis and Crystal Structure (2001) (1)
- Carbon Monoxide is an Inhibitor of HIF Prolyl Hydroxylase Domain 2 (2021) (1)
- Synthesis and New Crystal Structure of 1,1,3,3-Tetramethyl-1,3-Disila-2-Oxa[3] Ferrocenophane (2001) (1)
- Ruthenium Anticancer Agents En Route to the Tumor (2017) (1)
- Platinum(terpyridine) complexes with N-heterocyclic carbene co-ligands: high antiproliferative activity and low toxicity in vivo. (2023) (1)
- COTTON M EMORIAL SPECIAL ISSUE Linked Metal-cluster Systems: Isolation and Characterisation of {anti-[(p-cymene) RuCl]-l-[j-P,P;j-P-(PPh2CH2)3 CMe]-[AuPt3(CO)3(PCy3)3]}(PF6)2 (2008) (0)
- Antitumour and Anti-HIV Applications of PGMs (2008) (0)
- CCDC 1402549: Experimental Crystal Structure Determination (2017) (0)
- Back Cover: Functionalization of Ruthenium(II)(η6‐p‐cymene)(3‐hydroxy‐2‐pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies (ChemPlusChem 6/2017) (2017) (0)
- Adduct formed after 1 month in the reaction of dichlorido(1,3-dimethylbenzimidaz ol-2-ylidene)(eta5-pentamethylcyclopentadienyl)rhodium(III) with HEWL (2020) (0)
- CCDC 1402551: Experimental Crystal Structure Determination (2017) (0)
- Letters to a Young Chemist. Herausgegeben von Abhik Ghosh. (2011) (0)
- Cobalt complexes as internal standards for capillary zone electrophoresis–mass spectrometry studies in biological inorganic chemistry (2017) (0)
- Ligand Design in Medicinal Inorganic Chemistry. Herausgegeben von Tim Storr. (2015) (0)
- Could the Histone Proteins that Package DNA into Chromatin be Neglected Therapeutic Targets (2015) (0)
- Hydrazone- and imine-containing [PdPtL4]4+ cages: a comparative study of the stability and host-guest chemistry. (2022) (0)
- Cover Picture: A glucose derivative as natural alternative to the cyclohexane‐1,2‐diamine ligand in the anticancer drug oxaliplatin? (ChemMedChem 4/2007) (2007) (0)
- Abstracts of the 13th International Conference on Biological Inorganic Chemistry (2007) (0)
- Probing the Paradigm of Promiscuity for N‐Heterocyclic Carbene Complexes and their Protein Adduct Formation (2021) (0)
- Application of Mass Spectrometric Techniques to Delineate the Modes-of-Action of Anticancer Metallodrugs (2013) (0)
- Targeting Epigenetic Vulnerabilities of Cancer Cells by Exploiting Chromatin Structure and Chemistry (2016) (0)
- Ruthenium(II)(cymene)(chlorido)2-lysozyme adduct with two binding sites (2017) (0)
- Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes (2013) (0)
- Adducts formed after 1 month in the reaction of dichlorido(1,3-dimethylbenzimidazol-2-ylidene)(eta6-p-cymene)osmium(II) with HEWL (2020) (0)
- Contents list. (2017) (0)
- The aqueous stability and interactions of organoruthenium compounds with serum proteins, cell culture medium, and human serum (2022) (0)
- Anticancer Ru and Os complexes of N-(4-chlorophenyl)pyridine-2-carbothioamide: Substitution of the labile chlorido ligand with phosphines. (2022) (0)
- CCDC 1402550: Experimental Crystal Structure Determination (2017) (0)
- Organometallics in Cancer Treatment—Non-conventional Structures and Modes of Action (2018) (0)
- 5. Bioinspired Catalysis (2007) (0)
- List of Contributors (2019) (0)
- N-(4-Benzoylphenyl)pyridine-2-carbothioamide (2016) (0)
- CCDC 1402552: Experimental Crystal Structure Determination (2017) (0)
- A solid support-based synthetic strategy for the site-selective functionalization of peptides with organometallic half-sandwich moieties. (2021) (0)
- Metal containing complexes with anticancer properties. (2011) (0)
- CCDC 1507689: Experimental Crystal Structure Determination (2017) (0)
- The interaction of chlorido(1,5-cyclooctadiene)([4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1,3-dimethyl-1H-imidazol-3-ide])rhodium(I) with HEWL after 1 month (2020) (0)
- Osmium(II)(cymene)(chlorido)2-lysozyme adduct with one binding site (2017) (0)
- 8th Asian Biological Inorganic Chemistry Conference (2017) (0)
- Inside Back Cover: An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin (Angew. Chem. Int. Ed. 28/2017) (2017) (0)
- Crystallographic report: Crystal structure of 1-bromo-1'-[(2S)-N-(1-hydroxy-3-methylbutane-2-yl)]-ferroceneamide (2003) (0)
- Innenrücktitelbild: Ein Organoruthenium‐Tumortherapeutikum mit unerwartet hoher Selektivität für Plectin (Angew. Chem. 28/2017) (2017) (0)
- An Organorhodium Anticancer Agent with a Non-conventional Mode of Action Based on a Histone Deacetylase Inhibitor and a Plectin-targeting Agent (2020) (0)
- AsBIC8 -8th Asia/Pacific Biological Inorganic Chemistry Conference. (2017) (0)
- CCDC 663503: Experimental Crystal Structure Determination (2008) (0)
- The interaction of dichlorido(3-(anthracen-9-ylmethyl)-1-methylimidazol-2-ylidene)(eta6-p-cymene)ruthenium(II) with HEWL after 1 week (2021) (0)
- Ferrocene-Derived Palladium(II)-Based Metallosupramolecular Structures: Synthesis, Guest Interaction, and Stimulus-Responsiveness Studies. (2023) (0)
- Capillary electrophoresis hyphenated to inductively coupled plasma‐mass spectrometry: A novel approach for the analysis of anticancer metallodrugs in human serum and plasma (2008) (0)
- Synthesis, structure and fluxionality of Co(III) complexes containing chelated sulfate (2020) (0)
- Understanding the interactions of diruthenium anticancer agents with amino acids (2018) (0)
- Editorial [Hot Topic: Metal Containing Complexes with Anticancer Properties (Guest Editors: A. Nazarov & C. Hartinger)] (2011) (0)
- CCDC 663504: Experimental Crystal Structure Determination (2008) (0)
- Ruthenium(II)(cymene)(chlorido)2-lysozyme adduct formed when ruthenium(II)(cymene)(bromido)2 underwent ligand exchange, resulting in one binding site (2017) (0)
- Adducts formed after 3 weeks in the reaction of chlorido[chlorido(2,2'-((2-([2,2':6',2''-Terpyridin]-4'-yloxy)ethyl)azanediyl)bis(ethan-1-ol))platinum(II)] with HEWL (2021) (0)
- Targeting organometallic anticancer agents (2011) (0)
- 8th Asian Biological Inorganic Chemistry Conference (2017) (0)
- Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies (2012) (0)
- Cellular uptake and DNA damaging properties of platinum nanoparticles (2011) (0)
- Design of ruthenium-based small molecules as potential therapeutic agents (2009) (0)
- Triazolyl- vs Pyridyl-Functionalized N-Heterocyclic Carbene Complexes: Impact of the Pendant N-Donor Ligand on Intramolecular C–C Bond Formation (2022) (0)
- The interaction of chlorido(1,5-cyclooctadiene)([4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1,3-dimethyl-1H-imidazol-3-ide])rhodium(I) with HEWL after 1 week (2020) (0)
- Letters to a Young Chemist. Edited by Abhik Ghosh. (2011) (0)
- CCDC 783005: Experimental Crystal Structure Determination (2011) (0)
- Design of organoruthenium complexes for nanoparticle functionalization (2019) (0)
- Foreword to special issue on International Symposium on Bioorganometallic Chemistry (ISBOMC'14) (2015) (0)
- Adducts formed after 1 month in the reaction of dichlorido(1,3-dimethylbenzimida zol-2-ylidene)(eta5-pentamethylcyclopentadienyl)iridium(III) with HEWL (2020) (0)
- Determination of Relative Stabilities of Metal‐Peptide Bonds in the Gas Phase (2021) (0)
This paper list is powered by the following services:
Other Resources About Christian Hartinger
What Schools Are Affiliated With Christian Hartinger?
Christian Hartinger is affiliated with the following schools:
